Want to see STLN full AI Analyst Report?

Starling Oncology Institute (STLN) Price & Analysis

211 Followers

STLN Stock Chart & Stats

$5.19

$0.21(4.22%)

At close: Jul 27 4:00 PM EDT

$5.19

$0.21(4.22%)

Day’s Range― - ―

52-Week Range$2.32 - $7.05

Previous Close$5.21

VolumeN/A

Average Volume (3M)1.95M

Market Cap

$640.89M

Enterprise Value$622.84

Total Cash (Recent Filing)$30.28M

Total Debt (Recent Filing)$104.86M

Price to Earnings (P/E)―

Beta1.92

Next Earnings

Nov 11, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding99,982,930

10 Day Avg. Volume1,978,047

30 Day Avg. Volume1,952,546

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)-209.23

Price to Sales (P/S)6.54

P/FCF Ratio-118.37

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$9.25

Price Target Upside78.23% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.14

Revenue Forecast (FY)$650.95M

Bulls Say, Bears Say

Bulls Say

Specialty Pharmacy ScaleRapid specialty pharmacy expansion has materially increased gross profit and procurement scale. Durable demand for oncology drugs and improved supply economics support recurring revenue and cash generation, enabling operating leverage that can sustainably bolster margins and free cash flow over coming quarters.

Capitated Contract WinsLarge delegated and exclusive capitated agreements shift revenue toward predictable per-member payments, aligning incentives for cost-effective care. As managed lives scale, the business gains recurring revenue, stronger revenue visibility, and potential margin improvements from pathway-driven care — benefits that accrue over multiple quarters.

Refinancing And Liquidity ProgressReplacing convertible debt with a longer‑dated term loan reduced near‑term refinancing pressure and avoided dilution. Coupled with recent reported operating and free cash flow improvement, the refinancing meaningfully lengthens runway and lowers short‑term liquidity risk, improving financial flexibility over the next several quarters.

Bears Say

Negative Stockholders' EquityPersistently negative equity reflects accumulated losses and constrains financial flexibility. This structural weakness increases sensitivity to operational setbacks, complicates access to unsecured capital, and raises solvency risk if profitability or cash flow improvements stall during capitation scale‑up over the next 2–6 months.

Historical Cash-Flow DeficitDespite recent quarter improvements, the company has not demonstrated consistent multi‑period positive cash generation. Continued reliance on external capital remains a structural vulnerability; any delays in capitated revenue onboarding or pharmacy margin normalization could force additional financing and pressure operations over the medium term.

High Medical Loss Ratio (MLR)An elevated and volatile MLR materially compresses healthcare gross margins and reduces the benefit of higher capitation revenue until care pathways and utilization normalize. Persistent MLRs near 80%–90% limit sustainable earnings conversion and increase the execution burden on clinical management to deliver durable margin gains.

Starling Oncology Institute News

Starling Oncology price target raised to $11 from $8 at B. Riley

B. Riley raised the firm’s price target on Starling Oncology (STLN) to $11 from $8 and keeps a...

3d ago

STLN

Starling Oncology Institute: Robust Q2, Raised FY26 Outlook and Expanded Delegated Contracts Support Buy Rating and Unchanged $7 Price Target

Matthew Shea, an analyst from Needham, reiterated the Buy rating on Starling Oncology Institute. The associated price target...

3d ago

STLN

STLN FAQ

What was Starling Oncology Institute’s price range in the past 12 months?

Starling Oncology Institute lowest stock price was $2.32 and its highest was $7.05 in the past 12 months.

What is Starling Oncology Institute’s market cap?

Starling Oncology Institute’s market cap is $640.89M.

When is Starling Oncology Institute’s upcoming earnings report date?

Starling Oncology Institute’s upcoming earnings report date is Nov 11, 2026 which is in 93 days.

How were Starling Oncology Institute’s earnings last quarter?

Starling Oncology Institute released its earnings results on Aug 06, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.064 by -$0.016.

Is Starling Oncology Institute overvalued?

According to Wall Street analysts Starling Oncology Institute’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Starling Oncology Institute pay dividends?

Starling Oncology Institute does not currently pay dividends.

What is Starling Oncology Institute’s EPS estimate?

Starling Oncology Institute’s EPS estimate is -0.04.

How many shares outstanding does Starling Oncology Institute have?

Starling Oncology Institute has 99,982,930 shares outstanding.

What happened to Starling Oncology Institute’s price movement after its last earnings report?

Starling Oncology Institute reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.064. Following the earnings report the stock price went up 28.457%.

Which hedge fund is a major shareholder of Starling Oncology Institute?

Currently, no hedge funds are holding shares in STLN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Starling Oncology Institute Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

2.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Starling Oncology Institute

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

Starling Oncology Institute (STLN) Earnings & Revenues

Historic Earnings Reports

STLN Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlighted strong revenue growth (34.6% YoY), robust Specialty Pharmacy performance (57.6% revenue growth; 85.1% gross profit growth), improved margins and the company's second profitable quarter as a public company with positive adjusted EBITDA. Cash flow turned positive, free cash flow improved materially, and a refinancing strengthened the balance sheet without dilution. Management also announced meaningful capitated contract wins that add substantial lives and annualized capitation revenue, and they launched a provider portal expected to drive longer-term clinical and commercial benefits. Headwinds include a materially higher MLR (85.5% in Q2 vs 71% prior year), a steep decline in Patient Services gross profit (~57% YoY decline), timing delays that push some launches into Q4 and potential variability in pharmacy margin gains. Overall, the positive top-line, profitability improvement, cash flow progress and balance sheet actions outweigh the near-term operational and margin challenges while scaling capitated lives.View all STLN earnings summaries

STLN Stock 12 Month Forecast

Average Price Target

$9.25

▲(78.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","12":"$12","3.75":"$3.75","6.5":"$6.5","9.25":"$9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.86,5.332307692307692,5.804615384615385,6.276923076923077,6.74923076923077,7.2215384615384615,7.693846153846154,8.166153846153847,8.638461538461538,9.11076923076923,9.583076923076923,10.055384615384614,10.527692307692307,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.86,5.197692307692308,5.535384615384616,5.8730769230769235,6.210769230769231,6.548461538461539,6.886153846153846,7.223846153846154,7.561538461538461,7.899230769230769,8.236923076923077,8.574615384615385,8.912307692307692,{"y":9.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.86,5.024615384615385,5.189230769230769,5.353846153846154,5.518461538461539,5.683076923076923,5.8476923076923075,6.012307692307692,6.176923076923077,6.341538461538462,6.506153846153846,6.670769230769231,6.835384615384616,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.86,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >